This study sought to assess the long-term predictive value and net reclassification for risk of cardiovascular disease (CVD) of biomarkers reflecting oxidation-specific epitopes (OSEs).
Background
OSEs are immunogenic, proinflammatory, and proatherogenic. The long-term predictive value and net reclassification of OSEs for risk of CVD events are not known.
Methods
Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) and immunoglobulin (Ig)-G (IgG) and IgM autoantibodies to malondialdehyde-modified, low-density lipoprotein (MDA-LDL) and copper-oxidized LDL (Cu-OxLDL) were measured in 765 subjects in 1995 and 656 subjects in 2000 in the Bruneck study, representing 45-to 84-year-old men and women from the general community.
Results
Over 15 years of follow-up, 138 subjects reached the primary endpoint of incident CVD (ischemic stroke, myocardial infarction, new-onset unstable angina, acute coronary interventions, and vascular death). In a multivariable Cox model, the highest tertile of OxPL/apoB was associated with higher risk of CVD (hazard ratio [HR]: 2.4; 95% confidence interval [CI]: 1.5 to 3.7) and stroke (HR: 3.6; 95% CI: 1.8 to 7.4) compared with the lowest tertile. IgG Cu-OxLDLs were associated with higher risk of CVD, whereas IgM MDA-LDLs were associated with lower risk. Using OxPL/apoB, IgG Cu-OxLDL, and IgM MDA-LDL variables, the area under the curve (AUC) for CVD risk prediction increased from 0.664 (95% CI: 0.629 to 0.697) to 0.705 (95% CI: 0.672 to 0.737) (p ϭ 0.048). The net reclassification index (NRI) was 0.163 (p ϭ 0.0044) and 0.332 (p Ͻ 0.0001) in all subjects (n ϭ 765) and in subjects with intermediate risk (n ϭ 305), respectively. Of 627 subjects who remained free of CVD, 108 were correctly reclassified to a lower risk category, and 83 were reclassified to a higher category (categories: 15-year risk Ͻ15%, 15% to 30%, Ͼ30%).
Conclusions
OSE biomarkers predict 15-year CVD and stroke outcomes and provide potential clinical utility by reclassifying a significant proportion of individuals into higher or lower risk categories after traditional risk assessment. Atherosclerosis is initiated early in human life in an occult manner due to a variety of genetic, environmental, and behavioral risk factors, and is the leading cause of cardiovascular disease (CVD) events. It originates by the generation of subintimal macrophage foam cells that arise mainly due to the accumulation of oxidized lipids through unregulated uptake by macrophage scavenger receptors, an arm of the innate immune response in removing toxic substances to protect the host (1, 2) . After a long latent period of integrative and detrimental insults to the vessel wall, such as oxidation and chronic inflammation (3) (4) (5) , it manifests clinically as either symptomatic obstructive disease, such as angina or claudication, or acute atherothrombosis, such as myocardial infarction and ischemic stroke.
Various degrees of subclinical atherosclerosis are almost universally present in people living in Western societies (6) . However, the assessment of the specific future risk that subclinical atherosclerosis confers is difficult to assess at the individual level, even with invasive and expensive testing. This is due to the variable nature of its clinical expression, which is in part a consequence of the qualitative differences in plaque components in similar sized lesions. Furthermore, the current clinical paradigm of treating asymptomatic patients is appropriately focused on treating underlying risk factors and is not generally centered on treating only those patients with documented presence of atherosclerosis. In addition, aside from hypolipidemic therapies, specific treatments that target pathogenic mechanisms leading to clinical events, such as the oxidative, immune, and inflammatory components, do not yet exist.
In that regard, plasma biomarkers of CVD risk that provide value to easily measured clinical and laboratory variables are needed (7) . In particular, biomarkers that function as a link between risk factors and clinical CVD and are also putatively involved in causal pathways of atherosclerosis would be an attractive addition to the clinical armamentarium. Oxidation-specific epitopes (OSEs), present in plasma on circulating lipoproteins and lipoprotein (a) [Lp(a)] and in the vessel wall on lipoproteins, apoptotic cells, and matrix proteins, are strong candidates as potentially causal biomarkers more proximal to the atherosclerotic disease process (8) . OSEs represent "danger-associated molecular patterns (DAMPs)" (2) that are proinflammatory and are integrally involved in oxidative, innate, and adaptive immune responses. In this 15-year prospective study from the Bruneck population, we hypothesized that measurements reflecting risk from OSEs would predict the development of new CVD events and add clinical utility to established risk factors.
Methods
Study subjects. The Bruneck Study is a prospective population-based survey of the epidemiology and pathogenesis of atherosclerosis in a sex-and age-stratified random sample of all inhabitants of Bruneck, Italy (125 women and 125 men in their fifth to eighth decades [n ϭ 1,000]) (9) . The present study focuses on blood samples from the 1995 examination and the follow-up period for clinical events between 1995 and 2010 (100% follow-up). In 1995, the study population consisted of 826 subjects, and plasma samples for assessment of oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) were available in a random subsample of 765 subjects. The appropriate ethics committees approved the study protocol, and all study subjects gave written informed consent before entering the study. All risk factors were assessed by validated standard procedures. Study methodology and laboratory methods for factors listed in Table 1 were previously described in detail (9) (10) (11) . Determination of OSEs on lipoproteins. OxPL/apoB levels and immunoglobulin-G (IgG) and IgM autoantibodies to malondialdehyde-modified, lowdensity lipoprotein (MDA-LDL) and copper-oxidized (Cu-OxLDL) and apoB-immune complexes (apoB-IC) were measured in 765 subjects from the 1995 time point and in 656 subjects from the 2000 time point. OxPL/apoB levels were measured, as previously described, by chemiluminescent enzymelinked immunosorbent assay using the murine monoclonal antibody E06, which binds to the phosphocholine (PC) head group of oxidized but not native phospholipids (10) . When the OxPL/apoB levels in Bruneck were first published (10), they were reported in 2 ways: as relative light units (RLUs) and as a ratio of E06 (OxPL RLUs) binding to presence of apoB on the plate, measured by monoclonal antibody MB47 (apoB RLUs) (i.e., OxPL/ apoB ratio), as previously described (10, 12) . It was demonstrated that these measurements provided nearly identical results and were essentially interchangeable, thus subsequent studies reported OxPL/apoB as RLUs due to the more simplistic methodology of their determination. In the present analysis, we show both levels, but the analyses are based on OxPL/apoB RLU data. IgG and IgM autoantibodies, apoB-IC, and Lp(a) were measured as previously described (13) (14) (15) . The intra-and interassay coefficients of variation for OxPL/apoB were 6% to 10%. The University of California-San Diego Human Research Protection Program approved these studies. We previously showed that these biomarkers are stable with prolonged freezing or transport to processing sites on ice (10, 16, 17 Values are mean Ϯ SD, median (interquartile range) †, or %. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129. *Antioxidant supplements include vitamins A, C, and E, and selenium. No subjects were taking beta-carotene. †Median and interquartile range are presented for markedly skewed variables.
ADA ϭ American Diabetes Association: apoB ϭ apolipoprotein B; BP ϭ blood pressure; apoB-IC ϭ apoB-immune complexes; CRP ϭ C-reactive protein; Cu-OxLDL ϭ copper-oxidized low-density lipoproteins; CVD ϭ cardiovascular disease; HDL ϭ high-density lipoprotein; Ig ϭ immunoglobulin; LDL ϭ low-density lipoprotein; Lp-PLA 2 ϭ lipoprotein-associated phospholipase A 2 activity; MDAϭ malondialdehyde; OxPL/ApoB ϭ oxidized phospholipids on apolipoprotein B-100; RLU ϭ relative light unit. (22), and the integrated discrimination index (IDI), which integrates the NRI over all possible cutoffs and is equivalent to the difference in discrimination slopes (21) (all measures of reclassification).
Comparison of the C statistics and Harrell's C for models, including and not including OSE markers, was performed according to the method of DeLong (23) and with the STATA procedures "somersd" and "lincom," respectively. NRIs were calculated across categories of predicted 15-year risk of Ͻ15%, 15% to 30%, and Ͼ30%. All reported p values are 2-sided.
Results
Baseline characteristics. Table 1 displays the baseline characteristics of study subjects (n ϭ 765) according to incident CVD during follow-up (1995 to 2010). Subjects who developed the primary CVD endpoint (n ϭ 138) were more likely to be older and male, have higher levels of LDL cholesterol, vascular, coagulation, inflammatory, and anthropomorphic and activity risk factors, and to have preexistent CVD at study entry in 1995. OxPL/apoB levels and lipoprotein-associated phospholipase A 2 activity levels were higher in patients with incident CVD. In contrast, IgM antibodies to MDA-LDL, CuOxLDL, and apoB-IC were lower in subjects with CVD events, with the latter 2 associations achieving significance. IgG Cu-OxLDL antibodies tended to be higher in patients with subsequent CVD. Within-person variability of these markers was generally low. The regression dilution ratio of measurements taken 5 years apart was 0. OxPL/apoB and incident CVD. The risk of the primary composite CVD endpoint increased across tertiles of OxPL/ apoB and was particularly prominent in tertile 3 ( Table 2) . These associations were consistent across 3 models of multivariable adjustment: 1) following adjustment for age, sex, and previous CVD; 2) in a multivariable Cox model of 13 clinical variables, including high-sensitivity C-reactive protein (hsCRP); and 3) in the same Cox model with "usual" OxPL/apoB levels that considered the variability of Squares and lines are hazard ratios (HRs) and 95% confidence intervals. HRs were derived from Cox models and calculated for OxPL tertile groups (left-hand columns) and for a 1-SD unit increase in OxPL level (right-hand columns). In all analyses, only the first outcome event occurring in study participants was considered, whereas potential further or recurrent events were censored. *The primary composite cardiovascular endpoint subsumes ischemic stroke, acute coronary artery disease, and vascular death. The extended composite cardiovascular endpoint additionally considers TIAs and all revascularization procedures. Acute coronary artery disease subsumes myocardial infarction (fatal and nonfatal), new-onset unstable angina, acute coronary interventions, and sudden cardiac deaths. Vascular deaths subsume deaths due to ischemic stroke, myocardial infarction, sudden cardiac death, and aortic aneurysm rupture. †Multivariable adjustment: age, sex, previous cardiovascular disease, systolic blood pressure, smoking, diabetes, ferritin level, LDL and HDL cholesterol, alcohol consumption, social status, sports activity (Baecke score), and log e -transformed levels of C-reactive protein. ‡"Usual" OxPL levels were used instead of baseline levels. "Usual" OxPL level considers the variability of OxPL over time and was estimated by multivariate regression calibration. §Multivariable adjustment as previously described plus statin medication, platelet inhibitor medication, and antioxidant supplement use. Abbreviations as in Table 1 . (Table 2 ). All analyses were repeated using Lp(a) concentrations instead of OxPL/ apoB levels, and similar results were obtained. Cumulative hazard plots depicting the composite CVD endpoint (Fig. 1A) and stroke (Fig. 1B) indicated a progressive divergence in event frequency over 15-year follow-up in OxPL/apoB tertile 3 compared with tertiles 1 and 2.
Subgroup analysis revealed consistent findings across sex, age, CVD risk factors, Lp-PLA 2 activity, hsCRP, and FRS for both the tertile analysis and as continous variables for a 1-SD change for the primary composite CVD endpoint (Fig. 2) and for stroke as an individual endpont (Fig. 3) .
Association of Oxidation-specific Biomarkers With Cardiovascular Disease Risk in the Bruneck Study Cohort (1995 to 2010) (n ‫؍‬ 765) 
Receiver-operating classification curves and reclassification.
Receiver-operating classification curves for the primary endpoint were determined (Fig. 4) . With inclusion of the oxidation markers (OxPL/apoB, Cu-OxLDL IgG, and MDA IgM), the area under the curve (AUC) increased from 0.664 (0.629 to 0.697) (FRS only) to 0.705 (0.672 to 0.737). This change, although modest (⌬ AUC 0.042; 0.001 to 0.083, p ϭ 0.048), was statistically significant. The NRI was 16.3% (2-sided p ϭ 0.0044). Of 138 subjects with incident CVD, 35 were correctly reclassified to a higher risk category, 18 were reclassified to a lower category. In subjects who remained free of CVD [n ϭ 627], 108 were correctly reclassified to a lower risk category, and 83 were reclassified to a higher category (categories of 15-year risk: Ͻ15%, 15% to 30%, Ͼ30%). Similar to other new biomarkers in vascular medicine, the NRI was higher in subjects at intermediate risk (33.2%; n ϭ 305; p Ͻ 0.001).
In accordance with these findings, Harrell's C index increased from 0.675 to 0.705 (⌬ C index 0.029; Ϫ0.005 to 0.064; p ϭ 0.098), and the corresponding NRI, based on the previous 15-year risk categories (Ͻ15%, 15% to 30%, Ͼ30%), was 14.0% (2.6 to 25.3) (p ϭ 0.016) ( Table 4) , whereas the category-free continuous NRI and the IDI, which integrates the NRI over all possible cutoffs, were 37.6% (17.6 to 57.6; p Ͻ 0.001) and 0.052 (0.027 to 0.076; p Ͻ 0.001), respectively. The largest discrimination improvement was afforded by OxPL/apoB (AUC 0.664 to 0.698). Addition of the 2 other markers further increased the AUC from 0.698 to 0.705. In this population, both risk discrimination and risk reclassification improved significantly upon addition of all 3 parameters.
Discussion
This study demonstrates the clinical value of oxidationspecific biomarkers in predicting CVD events and stroke over a prospective 15-year follow-up in an unselected population from the general community. Individually, OxPL/apoB and IgG Cu-OxLDL autoantibodies predicted a higher event rate, whereas IgM MDA-LDL (or IgM Cu-OxLDL) autoantibodies predicted a lower event rate. Collectively, they significantly improved the predictive accuracy of CVD events in a model adjusting for 16 clinical variables, including hsCRP. Importantly, they allowed reclassification of subjects at initial low-, intermediate-, and high-risk categories, moving a significant number of subjects into both higher and lower categories. Because the Bruneck population reflects individuals seen in a primary care setting, broad application of oxidation-specific biomarkers, in addition to currently available clinical and laboratory risk factors, would allow optimal risk prediction and tailored therapies to appropriately match the risk with the intensity of treatment and follow-up.
These data support the unifying hypothesis that OSEs, such as OxPL and MDA epitopes, represent DAMPs that are detrimental to the host, and that the innate immune Squares and lines are hazard ratios and 95% CIs calculated for a 1-SD unit increase in OxPL/apoB. The size of squares reflects the number of individuals in each subgroup. All models were adjusted for age, sex, previous CVD, systolic blood pressure, smoking, diabetes, ferritin level, fibrinogen level, LDL and high-density cholesterol, waist-to-hip ratio, alcohol consumption, social status, Lp-PLA 2 activity, sports activity (Baecke score), uric acid level, fasting glucose, and log e -transformed levels of CRP and urinary albumin. Interactions were calculated by inclusion of appropriate interaction terms. Abbreviations as in Figures 1 and 2 .
2225 JACC Vol. 60, No. 21, 2012 Tsimikas et al. November 20/27, 2012 November 20/27, :2218 OSE, 15-Year CVD Events, and Net Reclassification system provides protective responses to them (2, 24) . Such DAMPs are strongly present on apoptotic cells (25, 26) , infectious pathogens such as pneumococcus (27) , and oxidized lipids (28, 29) . In response to such DAMPs, evolutionary processes have preserved and amplified innate immune effector proteins to bind and neutralize their proinflammatory effects. The initial evolutionary pressure may have been derived from the need to clear trillions of apoptotic cells on a daily basis, which may have been subsequently amplified by repeated exposure to common infectious pathogens that share similar epitopes or molecular mimics (2), as well as oxidized lipids derived from the diet and those generated in vivo following oxidative stress in the setting of dyslipidemia and other risk factors. These innate effector proteins are represented by a variety of macrophage scavenger receptors, IgM natural antibodies such as E06, and IgM autoantibodies measured in this study (29) , as well as innate plasma proteins, such as CRP, which binds not only the PC headgroup of OxPL, but the same PC (not as part of a phospholipid) on the cell wall of Streptococcus pneumoniae (30) . Recently, we demonstrated that complement factor H (CFH), which is a primary regulator of the alternative pathway of complement activation, strongly binds to MDA epitopes (24) . The loss of function single nucleotide polymorphism Y402 of CFH exhibited limited ability to bind MDA. The Y402 allele is a major risk factor for development of age-related macular degeneration, and importantly, loss of function by CFH in binding and preventing proinflammatory responses of MDA was directly linked to enhanced oxidative stress in the retina in a murine model. This suggests an important link between limiting inflammatory responses to MDA and age-related macular degeneration, a disease with many common risk factors and features to atherosclerosis. Overall, this study supports the notion that OSEs are important factors in immuneinflammatory diseases such as CVD, and that their measurement may serve as useful biomarkers of CVD risk assessment and event prediction.
The clinical role of autoantibodies to OxLDL has progressively evolved since the first demonstration of their presence in human and animal experimental lesions Ͼ20 years ago (28, (31) (32) (33) . The totality of data suggests that IgG autoantibodies are positively associated with anatomical CVD, whereas IgM autoantibodies are inversely associated. This area has been controversial due to mixed results arising for a variety of factors related to lack of prospective studies, small cohorts, lack of adequate power and extended followup. In addition, there has been a lack of standardization of antigens to precisely measure their levels in comparative studies (34, 35) . The present study represents the longest prospective follow-up of any study evaluating such biomarkers and demonstrates that increased baseline levels of IgG autoantibodies to Cu-OxLDL predict higher risk of cardiovascular events. Whether this increased risk association is a reflection of primary antibody mediated risk, for example, through proinflammatory effects mediated Table 1 .
by fragment-dependent events, or is simply a reflection that such IgGs are a surrogate of the presence of the enhanced generation of OSEs, cannot be determined from this clinical investigation. In contrast, IgM autoantibodies to OSEs were associated with lower incident CVD event rates and stroke. These data are in keeping with evolving experimental developments suggesting that IgM autoantibodies may be atheroprotective. 1) IgM OxLDL autoantibodies are highest in younger patients and decline as patients age, when CVD risk is highest (reviewed in [35] ). 2) OSEs represent a dominant, previously unrecognized target of IgM natural antibodies in both mice and humans, and ϳ30% of all natural antibodies bind to model OSEs, atherosclerotic lesions, and apoptotic cells (36) . The high prevalence of such OSE-specific natural antibodies suggests strong evolutionary pressure in protecting hosts from the proinflammatory effects of OSEs.
3) The natural antibody IgM E06/T15 has the capacity to block macrophage uptake of OxLDL, and generation of high titers of E06 in response to pneumococcal vaccination in cholesterol-fed LDLR Ϫ/Ϫ mice results in reduced atherosclerosis (27) . 4) Direct experimental evidence exists for a protective role of IgM autoantibodies in several different murine models of atherosclerosis; for example, the demonstration that the complete absence of B-1 cell-derived IgM led to accelerated atherosclerosis in LDLR Ϫ/Ϫ mice (37), and transfer of B-1 cells capable of secreting IgM into splenectomized apoE Ϫ/Ϫ mice was atheroprotective, but transfer of B-1 cells incapable of secreting IgM was not (38) . This suggests that natural IgM antibodies are evolutionarily selected in nature and play an important role in mediating homeostatic functions. In the case of CVD, the presence of circulating IgM may lead to prevention of foam cell formation, as has been shown with passive immunization of human antibodies (39) , and neutralization and/or clearance of apoptotic cells and other OSEs when generated by oxidative stress (36) . In this way, they provide a beneficial innate immune function when DAMPs are generated.
Unlike OxLDL autoantibodies that represent indirect measures of OSEs, OxPL/apoB represents a direct measure of OSEs in plasma. The measurement of OxPL/apoB has been now validated in a large clinical database (reviewed in Taleb et al. [8] ). OxPL/apoB levels reflect the presence of OxPL on apoB particles and are increased in a variety of atherogenic phenotypes (40, 41) . OxPL/apoB levels have been previously shown to correlate with Lp(a). Interestingly, they correlate best with Lp(a) in patients with high Lp(a) levels associated with small apo(a) isoforms, but do not correlate well in subjects with lower Lp(a) levels with large isoforms (42) . OxPL/apoB, therefore, seems to reflect the most atherogenic Lp(a) particles. Because patients have 2 different apo(a) isoforms that are not measured clinically (43, 44) , the OxPL/apoB measure is a clinically useful surrogate for these highly atherogenic Lp(a) particles and may represent a unifying measure of their cardiovascular risk.
In this study, the predictive value of oxidation-specific biomarkers was extended in several ways. 1) The availability of 2 separate measures over 5 years and their stability over this time (more reproducible than LDL-C levels [10, 40] ) allowed us to analyze and report the usual levels of OxPL/ apoB. This adds an enhanced level of robustness to the predictive value. 2) OxPL/apoB was predictive of stroke/ TIA as an individual endpoint with a robust HR of 3.6 over a 15-year follow-up. Because stroke is an increasing cause of mortality and morbidity globally, it may serve as an important risk stratifier, particularly with the dearth of available stroke biomarkers (45) . Such biomarkers will also be needed with the increasing aging of populations across the globe. 3) OxPL/apoB remained independently predictive of CVD over a prospective 15-year follow-up. 4) The fact that subjects in the third tertile of OxPL/apoB were as much higher risk than subjects in tertiles 1 and 2 may suggest a threshold effect of increasing CVD risk in patients with very high levels of OxPL/apoB. This needs to be validated in accumulating outcomes studies with this biomarker by plotting OxPL/apoB levels with risk of new CVD events and assessing for a threshold in risk prediction. The addition of OxPL/apoB, IgG, and IgM autoantibodies to the predictive models allowed enhanced risk prediction, and importantly, net reclassification of subjects into lower or higher risk categories. If these reclassification findings are confirmed in larger studies, it may allow clinically meaningful reclassification of primary care subjects into different categories, which would have significant public health implications from many perspectives, including prevention of events and cost of treatments. The OxPL/apoB assay has been recently licensed commercially and will be made available in the near future as a sendout laboratory measurement and as a kit for both clinical and research applications. Study limitations. Limitations of this study include that the subjects were all Caucasian, and these findings need to be verified in other racial populations.
Conclusions
A combination of direct and indirect oxidation-specific biomarkers provide robust, independent predictive value for CVD and stroke events and enhances the ability to reclassify subjects into lower or higher risk categories. These biomarkers may have clinical utility in a broad range of patients at risk for CVD.
